European Review for Medical and Pharmacological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2023-05-09 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：综合性期刊
经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30
%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教

56 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2020-12-04 12103978m50暂无昵称

新冠meta,24小时不到accept。修改格式语言后2天发付款链接

159 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2022-02-12 第五先生

偏重的研究方向：临床药理
经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度

91 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2020-11-11 ms7000002088020020

请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？

147 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2023-06-02 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：综合性期刊
经验分享：这个杂志的发表有办法的，能保证录用。

50 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2022-04-22 ms7000000507856696

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：癌症;药理;调查研究
经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月

54 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2020-07-21 WHNY

我才投，under consideration中，需要马上撤稿吗？

172 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2020-09-12 hech55

被打假打的这么厉害，online想撤稿，有没有什么好办法

136 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2021-02-10 12103978m50暂无昵称

官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了

136 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=904742, encodeId=fdc6904e4279, content=新冠meta,24小时不到accept。修改格式语言后2天发付款链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Fri Dec 04 06:42:15 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898537, encodeId=662589853e72, content=请问这个杂志有under review.的状态吗？还是说一直是under consideration呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=558a5381281, createdName=ms7000002088020020, createdTime=Wed Nov 11 18:48:07 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1213542, encodeId=c49a1213542c3, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：癌症;药理;调查研究 经验分享：感觉还是挺容易的，不过也得看文章方向，感觉他们喜欢药物作用研究的，从投稿到录用不到一个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Apr 22 23:09:34 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884772, encodeId=33c0884e72db, content=被打假打的这么厉害，online想撤稿，有没有什么好办法, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ecdd1390758, createdName=hech55, createdTime=Sat Sep 12 16:20:59 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924038, encodeId=d9be9240388a, content=官网文章已经一周了pubmed还搜索不到，是不是挨踢了，是不是pubmed都不收录了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Wed Feb 10 11:35:43 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=)]

2019-12-01 14766288m61暂无昵称

这个文章是不是只有under consideration的状态呀？

79 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务